查看购物车
  • Traditional Chinese
  • English
  • Japanese
2031年亚太地区生物製剂市场预测 - 区域分析 - 按产品、应用、来源和製造
市场调查报告书
商品编码
1764940

2031年亚太地区生物製剂市场预测 - 区域分析 - 按产品、应用、来源和製造

Asia Pacific Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing
出版日期: | 出版商: The Insight Partners | 英文 163 Pages | 订单完成后即时交付

价格

2023 年亚太生物製剂市场价值为 1,015.905 亿美元，预计到 2031 年将达到 4,170.829 亿美元；预计 2023 年至 2031 年的复合年增长率为 19.3%。

发展中地区生物技术发展推动亚太生物製剂市场

现代生物技术的许多应用都需要抗体，从基础研究到创新的医学治疗方法。治疗性抗体的开发为治疗各种疾病开闢了新的途径，证明了这些粒子的转化能力。抗体在诊断中也至关重要，因为它们提供了准确可靠的疾病识别方法。各国政府的支持日益增多、公私合作伙伴关係日益加强、疾病状况的不断变化以及资金活动的不断增加，正在广泛提升亚太地区、南美洲和中美洲以及中东和非洲等地区生物技术产业的业绩。阿联酋、沙乌地阿拉伯、阿曼、马斯喀特、巴林、台湾、马来西亚、印度、中国大陆、新加坡和日本等国家和地区是生物技术产业利润丰厚的市场。生物技术、遗传学和细胞生物学的进步有助于发现多种潜在的标靶治疗药物。生物技术是中国的战略产业。 「中国製造2025」计画强调支持高科技产品（包括创新药物）製造的研发能力。该计划旨在引导中国製药公司瞄准特定领域，以促进生物技术创新并提升出口。亚洲国家更注重利用基因组学、蛋白质组学和生物标记方面的进步进行诊断和治疗。因此，发展中地区生物技术产业的持续发展预计将在未来几年为生物製剂市场创造机会。

亚太生物製剂市场概览

亚太地区的生物製剂市场分为中国、日本、印度、韩国、澳洲和亚太其他地区。该地区的市场成长得益于大量患有遗传疾病的患者以及各国政府对医疗研发投入的增加。在过去几年中，中国人们对生物製剂益处的认识显着提高。此外，当地获得细胞株表征的各种测试服务的管道也有所增加，许多产品从临床前开发到商业化都有所发布，这对市场的成长产生了积极的影响。近年来，科学家和卫生当局致力于强调如何有效利用生物製剂来研究和治疗疾病以及开发药物和医疗器材。他们也努力加强对先天性残疾发展机制的认识。三星生物製剂公司已与中国生物技术公司 GeneQuantum Healthcare 签署合作协议，共同开发用于治疗非小细胞肺癌 (NSCLC)、三阴性乳癌 (TNBC) 和其他实体肿瘤的抗体药物偶联物 (ADC)。

亚太地区生物製剂市场收入及预测（2031年）（百万美元）

亚太地区生物製剂市场细分

亚太生物製剂市场分为产品、应用、来源、製造和国家。

根据产品类型，亚太生物製剂市场细分为单株抗体、疫苗、重组荷尔蒙/蛋白质、细胞和基因疗法以及其他。单株抗体在2023年占据了最大的市场。

从应用角度来看，亚太生物製剂市场主要分为癌症、传染病、自体免疫疾病等。 2023年，癌症领域占据了最大的市场。

依来源划分，亚太生物製剂市场分为哺乳动物生物製剂和微生物生物製剂。 2023年，哺乳动物生物製剂市场占有较大份额。

根据製造方式，亚太生物製剂市场分为外包和内部製造。 2023年，外包部分占据了更大的市场。

依国家划分，亚太生物製剂市场分为中国、印度、日本、韩国、澳洲和亚太其他地区。 2023年，中国占据了亚太生物製剂市场的主导地位。

AbbVie Inc、辉瑞公司、三星生物製品有限公司、ADMA Biologics, Inc.、无锡生物製品有限公司、Catalent Inc、AGC Biologics AS、阿斯利康公司、安进公司、Nitto Avecia 和 Quality Assistance sa 是亚太生物製剂市场的一些领先公司。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：亚太生物製剂市场－关键市场动态

  • 市场驱动因素
    • 慢性病盛行率不断上升
    • 倾向外包製造业务
  • 市场限制
    • 生物製剂成本高
  • 市场机会
    • 发展中地区生物技术的演变
    • 基因和细胞治疗在生物製剂领域的进展
  • 未来趋势
    • 企业的策略倡议
  • 驱动因素和限制因素的影响：

第五章：生物製剂市场－亚太地区分析

  • 2021-2031年亚太地区生物製剂市场收入
  • 亚太地区生物製剂市场预测分析

第六章：亚太生物製剂市场分析 - 按产品

  • 单株抗体
  • 疫苗
  • 重组荷尔蒙/蛋白质
  • 细胞和基因治疗
  • 其他的

第七章：亚太生物製剂市场分析－依应用

  • 癌症
  • 传染病
  • 自体免疫疾病
  • 其他的

第八章：亚太生物製剂市场分析 - 按来源

  • 哺乳动物
  • 微生物

第九章：亚太生物製剂市场分析－依製造

  • 外包
  • 内部

第十章：亚太生物製剂市场－国家分析

  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 亚太其他地区

第 11 章：产业格局

  • 概述
  • 市场倡议
  • 伙伴关係与合作
  • 其他发展

第十二章：公司简介

  • AbbVie Inc
  • Pfizer Inc
  • Samsung Biologics Co Ltd
  • ADMA Biologics, Inc.
  • WuXi Biologics Inc
  • Catalent Inc
  • AGC Biologics AS
  • AstraZeneca Plc
  • Amgen Inc
  • Nitto Avecia
  • Quality Assistance s.a.

第 13 章：附录

Product Code: BMIRE00031590

The Asia Pacific biologics market was valued at US$ 1,01,590.5 million in 2023 and is expected to reach US$ 4,17,082.9 million by 2031; it is estimated to register a CAGR of 19.3% from 2023 to 2031.

Evolution of Biotechnology in Developing Regions Fuels Asia Pacific Biologics Market

Antibodies are required in numerous applications in modern biotechnology, from fundamental research to innovative medical therapeutic approaches. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most lucrative markets for the biotechnology industry. Advancements in biotechnology, genetics, and cell biology have contributed to the identification of several potential therapeutics for targeted treatments. Biotechnology is a strategic sector for China. The Made in China 2025 initiative emphasizes on research capabilities supporting the manufacturing of high-tech products, including innovative medicines. The plan introduced Chinese pharmaceutical companies to target areas to spur biotechnology innovation and enhance exports. Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.

Asia Pacific Biologics Market Overview

The biologics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in the region is driven by a large pool of patients living with genetic conditions and increasing investments in healthcare R&D by governments of respective countries. Over the past few years, there has been a significant rise in awareness about the benefits of biologics in China. Moreover, there was a rise in local access to a broad range of testing services for cell line characterization and many release from preclinical development to commercialization, creating a positive impact on the growth of the market. In recent years, scientists and health authorities have made efforts to highlight how biologics could be effectively utilized to study and treat diseases and develop pharmaceuticals and medical devices. They are also striving to strengthen their knowledge based on the mechanism of development of congenital disabilities. Samsung Biologics has signed a partnership agreement with China Biotech GeneQuantum Healthcare for the development of antibody-drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors.

Asia Pacific Biologics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Biologics Market Segmentation

The Asia Pacific biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Asia Pacific biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Asia Pacific biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Asia Pacific biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Asia Pacific biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Asia Pacific biologics market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Asia Pacific biologics market.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Asia Pacific Biologics Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic Diseases
    • 4.1.2 Preference for Outsourcing Manufacturing Operations
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
  • 4.3 Market Opportunities
    • 4.3.1 Evolution of Biotechnology in Developing Regions
    • 4.3.2 Gene and Cell Therapy Advancements in Biologics
  • 4.4 Future Trends
    • 4.4.1 Strategic Initiatives by Companies
  • 4.5 Impact of Drivers and Restraints:

5. Biologics Market - Asia Pacific Analysis

  • 5.1 Asia Pacific Biologics Market Revenue (US$ Million), 2021-2031
  • 5.2 Asia Pacific Biologics Market Forecast Analysis

6. Asia Pacific Biologics Market Analysis - by Product

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Overview
    • 6.1.2 Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Vaccine
    • 6.2.1 Overview
    • 6.2.2 Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.3 Recombinant Hormones/Proteins
    • 6.3.1 Overview
    • 6.3.2 Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.4 Cell and Gene Therapy
    • 6.4.1 Overview
    • 6.4.2 Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Biologics Market Analysis - by Application

  • 7.1 Cancer
    • 7.1.1 Overview
    • 7.1.2 Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Infectious Diseases
    • 7.2.1 Overview
    • 7.2.2 Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Autoimmune Diseases
    • 7.3.1 Overview
    • 7.3.2 Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Biologics Market Analysis - by Source

  • 8.1 Mammalian
    • 8.1.1 Overview
    • 8.1.2 Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Microbial
    • 8.2.1 Overview
    • 8.2.2 Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Biologics Market Analysis - by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Overview
    • 9.1.2 Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 In-house
    • 9.2.1 Overview
    • 9.2.2 In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Biologics Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 China: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.2.2 China: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.2.3 China: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.2.4 China: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.3 India: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 India: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.3.2 India: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.3.3 India: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.3.4 India: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.4 Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 Japan: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.4.2 Japan: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.4.3 Japan: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.4.4 Japan: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.5 South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 South Korea: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.5.2 South Korea: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.5.3 South Korea: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.5.4 South Korea: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.6 Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 Australia: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.6.2 Australia: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.6.3 Australia: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.6.4 Australia: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.7 Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Manufacturing

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Market Initiative
  • 11.3 Partnerships and Collaborations
  • 11.4 Other Developments

12. Company Profiles

  • 12.1 AbbVie Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Samsung Biologics Co Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 ADMA Biologics, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 WuXi Biologics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Catalent Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AGC Biologics AS
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AstraZeneca Plc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Amgen Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Nitto Avecia
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Quality Assistance s.a.
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About Us

List Of Tables

  • Table 1. Asia Pacific Biologics Market Segmentation
  • Table 2. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Product
  • Table 4. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
  • Table 5. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Source
  • Table 6. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Manufacturing
  • Table 7. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 9. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 10. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 11. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 12. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 13. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 14. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 15. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 16. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 17. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 18. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 19. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 20. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 21. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 22. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 23. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 24. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 25. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 26. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 29. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 30. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 31. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing

List Of Figures

  • Figure 1. Asia Pacific Biologics Market Segmentation - Country
  • Figure 2. Asia Pacific Biologics Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Biologics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Biologics Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Asia Pacific Biologics Market Share (%) - by Application (2023 and 2031)
  • Figure 12. Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Asia Pacific Biologics Market Share (%) - by Source (2023 and 2031)
  • Figure 17. Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Asia Pacific Biologics Market Share (%) - by Manufacturing (2023 and 2031)
  • Figure 20. Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Asia Pacific Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)